Literature DB >> 14586395

Clinical trials: are these your patients?

William Storms1.   

Abstract

Many clinicians base their treatment choices on trial outcomes. To determine if clinical trial results apply to the general patient population, several factors need to be considered. The exclusion and inclusion of patients in a trial may present selection bias. Adherence to therapy in trials often varies widely compared with adherence seen in clinical practice. Endpoints used in trials compared with endpoints used in practice are not always comparable. The performance and publication of clinical trials can be affected by investigator or publication bias. Finally, reporting of data as mean values may not always relate to the outcome in individual patients. By understanding some of these issues, clinicians can begin to better relate trial results with patient treatment options.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586395     DOI: 10.1016/j.jaci.2003.09.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  9 in total

1.  Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.

Authors:  Edward C F Wilson; David Price; Stanley D Musgrave; Erika J Sims; Lee Shepstone; Jamie Murdoch; H Miranda Mugford; Annie Blyth; Elizabeth F Juniper; Jon G Ayres; Stephanie Wolfe; Daryl Freeman; Richard F T Gilbert; Elizabeth V Hillyer; Ian Harvey
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Estimation of Population Average Treatment Effects in the FIRST Trial: Application of a Propensity Score-Based Stratification Approach.

Authors:  Jeanette W Chung; Karl Y Bilimoria; Jonah J Stulberg; Christopher M Quinn; Larry V Hedges
Journal:  Health Serv Res       Date:  2017-08-21       Impact factor: 3.402

Review 3.  Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 4.  Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children.

Authors:  Francine M Ducharme; Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson
Journal:  Cochrane Database Syst Rev       Date:  2010-05-12

5.  External validity of randomised controlled trials in asthma: to whom do the results of the trials apply?

Authors:  Justin Travers; Suzanne Marsh; Mathew Williams; Mark Weatherall; Brent Caldwell; Philippa Shirtcliffe; Sarah Aldington; Richard Beasley
Journal:  Thorax       Date:  2006-11-14       Impact factor: 9.139

Review 6.  Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children.

Authors:  Muireann Ni Chroinin; Ilana Greenstone; Toby J Lasserson; Francine M Ducharme
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07

Review 7.  Day and Night Control of COPD and Role of Pharmacotherapy: A Review.

Authors:  Alberto Braghiroli; Fulvio Braido; Alessio Piraino; Paola Rogliani; Pierachille Santus; Nicola Scichilone
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-06-04

8.  Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study.

Authors:  David Price; Anne Robertson; Kevin Bullen; Cynthia Rand; Rob Horne; Heribert Staudinger
Journal:  BMC Pulm Med       Date:  2010-01-05       Impact factor: 3.317

9.  Comparison of Clinical Outcomes of Persons Living With HIV by Enrollment Status in Washington, DC: Evaluation of a Large Longitudinal HIV Cohort Study.

Authors:  Jenevieve Opoku; Rupali K Doshi; Amanda D Castel; Ian Sorensen; Michael Horberg; Adam Allston; Michael Kharfen; Alan E Greenberg
Journal:  JMIR Public Health Surveill       Date:  2020-04-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.